Biotechnology is the science of using biological systems — proteins, genes, cells, and organisms — to create medicines that treat diseases in ways traditional chemistry cannot. The sector has produced some of the most transformative medical advances of the past four decades: recombinant insulin, monoclonal antibodies, gene therapies, mRNA vaccines, and CAR-T cell therapies.
The global biotechnology market exceeded $1.3 trillion in total value in 2024, encompassing both standalone biotech companies and the biologics divisions of major pharmaceutical firms. Biotechnology is distinct from traditional pharmaceuticals in its reliance on biological manufacturing processes, its tolerance for long development timelines, and its extraordinary binary risk profile — companies can fail after spending a decade and a billion dollars in clinical trials if a drug fails its pivotal trial.
How Biotech Companies Make Money
Commercial Drug Revenue
A biotech company that has successfully brought a drug through clinical trials and regulatory approval earns revenue from drug sales — either directly or through a partnership with a larger pharmaceutical company.
Biologics (large-molecule drugs) maintain pricing power longer than small-molecule drugs because biosimilar manufacturing is technically complex, expensive, and regulatory-intensive. This means the post-patent-cliff revenue erosion for biologics is substantially slower than for traditional generics — often 20–40% market share loss in the first two years, compared to 80–90% for small-molecule drugs.
Licensing and Milestone Payments
Early-stage biotech companies frequently license their drug candidates to larger companies — receiving upfront payments, development milestone payments (paid at specific clinical or regulatory achievements), and royalties on eventual commercial sales.
This partnership model allows small biotechs to fund development with non-dilutive capital while accessing larger companies’ commercial infrastructure. Milestones can be lumpy revenue events — a $500 million Phase III milestone payment hitting in a single quarter can massively distort reported financials.
Contract Research and Manufacturing
Some biotechs generate revenue from contract research and manufacturing (CRO/CDMO services), leveraging their scientific or manufacturing capabilities to serve other companies. This provides a stable revenue base during clinical development.
Revenue Models Compared
| Model | Revenue Basis | Gross Margin |
|---|---|---|
| Commercial biologic drug sales | Net selling price × units | 70–90% |
| Small-molecule drug sales | Net selling price × units | 75–85% |
| Licensing and milestones | Contract terms | 90–100% |
| Royalties on licensed drugs | Percentage of partner’s net sales | 90–100% |
| Contract manufacturing (CDMO) | Manufacturing fee | 30–50% |
The Burn Rate Reality
Most biotech companies are pre-commercial — they have no revenue from drug sales and operate entirely on capital raised from investors. Their financial model is one of controlled spending: each quarter they burn cash on R&D and clinical trials, managed against their cash runway.
Cash runway (quarters of cash remaining at current burn rate) is the most important near-term metric for pre-commercial biotechs. Running out of cash before a Phase III readout forces either dilutive equity raises at distressed valuations or clinical programme abandonment.
Key Companies in Biotechnology
- Amgen — one of the world’s largest and oldest biotechs; Repatha, Enbrel, Otezla, bone health franchise
- Gilead Sciences — HIV (dominant with Biktarvy), HCV (Harvoni, Sovaldi), oncology
- Regeneron Pharmaceuticals — Dupixent (atopic dermatitis, asthma, COPD); Eylea; cancer antibodies
- Vertex Pharmaceuticals — dominant in cystic fibrosis (Trikafta); expanding into kidney and pain
- Moderna — mRNA platform; COVID-19 vaccine; pursuing RSV, cancer vaccines, rare disease
Key Metrics for Biotech Companies
Pipeline Stage and Readout Catalysts
The single most important driver of biotech stock performance is clinical trial results. Phase II and Phase III readouts are binary events — drug works or it does not. Tracking upcoming readout dates and the drug’s mechanism of action (does the biology support efficacy?) is essential for pipeline valuation.
Cash and Runway
Pre-commercial biotechs live and die by their cash balance. A company with 18 months of runway and a Phase III readout due in 6 months has a comfortable position. A company with 6 months of runway and no near-term catalysts is in crisis. Check the cash balance, quarterly burn rate, and runway in every earnings call.
Gross Margin
Commercial-stage biotechs earn very high gross margins — 70–90% — because drug manufacturing costs are low relative to net selling prices. Gross margin compression signals manufacturing scale-up challenges, royalty obligations, or product mix shift.
R&D Expense as Percentage of Revenue
For early-stage biotechs, R&D is the primary expenditure and often exceeds revenue. For commercial-stage biotechs, tracking R&D intensity over time reveals whether the company is investing in pipeline renewal or milking existing assets.
Price-to-Sales Ratio
For pre-commercial or fast-growing commercial biotechs, P/S (or EV/revenue) ratios are commonly used, since earnings are absent or unstable. Very high P/S multiples (10–20×+) are justified only when the pipeline has a high probability of adding substantial future revenue.
The mRNA Platform Revolution
Moderna’s COVID-19 vaccine was the world’s first mass-market mRNA product — proof that the mRNA platform could work at scale. mRNA vaccines and therapeutics work by delivering genetic instructions into human cells, prompting them to produce proteins that trigger immune responses or replace defective proteins.
The platform potential extends far beyond COVID: personalised cancer vaccines (Moderna has a Phase 3 mRNA-based melanoma vaccine in partnership with Merck), rare disease gene therapy, influenza vaccines, and RSV vaccines. Moderna’s revenue trajectory post-COVID depends almost entirely on its pipeline’s success.
Key Comparisons
Related Glossary Terms
- Gross Margin — the primary profitability metric for commercial biotech
- Free Cash Flow — the ultimate goal for biotech companies post-commercialisation
- Price-to-Sales Ratio — valuation metric for pre-commercial and high-growth biotechs
- Return on Invested Capital — the long-run R&D efficiency scorecard